Abstract
Recycling existing drugs for cancer therapy: delivering low cost cancer care.
Highlights
Drug repurposing is a strategy with fascinating potential for cutting the cost of cancer care as well as significantly affecting patient outcomes, with two of the most notable examples being Thalidomide and Sildenafil
Cancer Research UK has reached an agreement with AstraZeneca to take an experimental drug, originally designed for asthma, into a clinical trial to treat kidney cancer
The Repurposing Drugs in Oncology (ReDO) project, an international collaboration between researchers working for not-for-profit patient-centred organisations in Europe and the United States, aims to accelerate the repurposing of non-cancer drugs for new indications in oncology
Summary
This is despite the fact that all the research costs were covered by the original price, and the number of patients treated and the length of time they are on the drug have both vastly increased because of the drug’s success. Drug repurposing is a strategy with fascinating potential for cutting the cost of cancer care as well as significantly affecting patient outcomes, with two of the most notable examples being Thalidomide and Sildenafil.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
